Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HPGDS | O60760 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.52 |
| ▸ | USP2 | O75604 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NAMPT | P43490 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13147991 | 0.91 | NPY2R (0.59) | NPY2RMAPTGAAHPGDSCYP3A4 | |
| SCHEMBL3085763 | 0.88 | NPY2R (0.61) | NPY2RMAPTGAAHPGDSCYP3A4 | |
| SCHEMBL3081069 | 0.88 | CYP3A4 (0.62) | NPY2RMAPTGAAHPGDSCYP3A4 | |
| SCHEMBL13148001 | 0.87 | NPY2R (0.61) | NPY2RMAPTGAAHPGDSCYP3A4 | |
| SCHEMBL13180534 | 0.86 | HPGDS (0.61) | NPY2RMAPTGAAHPGDSCYP3A4 | |
| SCHEMBL13147994 | 0.84 | NPY2R (0.66) | NPY2RMAPTGAAHPGDSCYP3A4 | |
| SCHEMBL13180465 | 0.84 | NPY2R (0.58) | NPY2RMAPTGAAHPGDSCYP3A4 | |
| SCHEMBL13147992 | 0.83 | HPGDS (0.60) | NPY2RMAPTGAAHPGDSCYP3A4 | |
| SCHEMBL3094348 | 0.81 | MAPT (0.59) | NPY2RMAPTGAAHPGDSCYP3A4 | |
| SCHEMBL3086924 | 0.81 | EPHX2 (0.55) | NPY2RMAPTGAAHPGDSCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | claimed |
| EP-2150532-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | Evotec AG (DE) | 2010-02-10 | — | — | EP | claimed |
| WO-2008122787-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2008-10-16 | — | — | WO | claimed |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | disclosed |
| EP-2150532-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | Evotec AG (DE) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008122787-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, PTGDR, PTGIS | NPY2R 922/4885MAPT 4774/4885GAA 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.